European Medicines Agency approves licence extension to include reduced maintenance dose of certolizumab pegol in adult patients with axial spondyloarthritis

After at least 1 year of maintenance treatment with 200 mg every 2 weeks or 400 mg every 4 weeks, patients with sustained remission can be considered for a reduced maintenance dose of 200 mg every 4 weeks. Approval was based on data from Phase IIIb C-OPTIMISE trial.